bioAffinity: CyPath Lung test sales more than double through Q3 2026
bioAffinity Technologies reported CyPath Lung test sales rose more than 100% through Q3 2026 versus the prior-year period. Ordering physicians increased 89% in Q3 versus Q3 2025.
bioAffinity Technologies reported CyPath Lung test sales rose more than 100% through Q3 2026 versus the prior-year period. Ordering physicians increased 89% in Q3 versus Q3 2025.